Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostWritten by Chris Markoch. Article Published: 2/5/2026. 
What You Need to Know - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average the day after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer delivered adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 candidate. The Wall Street Journal is asking whether a stock market crash is coming. Research from Weiss Ratings suggests the first half of 2026 could be very tough for certain stocks as a radical shift hits the market. Some of America's most popular names could take serious damage. Analysts have identified five stocks you should consider avoiding before this event plays out. If these are in your portfolio, you'll want to review your positions carefully. See the five stocks to avoid and learn what's driving this shift. PFE stock closed up 4% on Feb. 4 as analysts and investors digested the results. The bullish thesis: while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and accelerating use of artificial intelligence across R&D. That story begins with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. Data shows the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035, a compound annual growth rate (CAGR) of about 9.7%. That growth helps explain why billions of dollars are pouring into the industry as companies try to carve out market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET-097i. The company reported results from its Phase 2b VESPER-3 study, which met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28 weeks. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom attributed the stock's gain to the positive clinical data. That may be true in the near term, but investors should recognize that GLP-1–driven rallies can be transient. Pfizer's GLP-1 drugs show promise, but it will take time for that to flow through to the company's financials. And the GLP-1 trade is expanding — not necessarily overcrowded, but competitive — as the earnings report from Eli Lilly & Co. (NYSE: LLY) makes clear: large pharma players are not ceding obesity leadership easily. There are other reasons to be bullish on PFE, notably its oncology portfolio. Business Research Insights values the global oncology drugs market at about $264.92 billion in 2026 and projects it to reach $648.08 billion by 2035, reflecting a CAGR of roughly 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had roughly 60 candidates in its pipeline — a large number of opportunities to capture market share. The portfolio was significantly strengthened after its acquisition of Seagen in 2023. Today, Pfizer's roster includes late-stage candidates such as Vepdegestrant — a next-generation targeted protein degrader (PROTAC) — paired with atirmociclib, a selective CDK4 inhibitor, which together target ER+/HER2- metastatic breast cancer in later-stage trials. Other late-stage programs include: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) for metastatic non-small cell lung cancer, leveraging Pfizer's Seagen-acquired ADC expertise.
- Sasanlimab, which targets bladder cancer; and a bispecific PD-1xVEGF agent (PF-4404) that is being combined with Padcev to treat urothelial cancer — positioning these agents to potentially become blockbusters amid oncology growth.
Pfizer could bring multiple drugs to market over the next five to ten years. That outlook is strengthened by the company's commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships like Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics. These alliances — and internal tools — accelerate target identification and decision-making. Internally, platforms such as "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) help optimize discovery and manufacturing. These AI efforts were critical to the company's rapid development of Paxlovid and support anticipated catalysts in oncology and obesity for 2026. Pfizer is targeting $1.2 billion in savings by 2027 through efficiency gains. Industry-wide, AI is projected to boost productivity by 35% to 45% by improving preclinical decision-making and streamlining trials, making it a core competitive edge rather than optional hype. Pfizer's early and broad adoption of AI tools should provide a meaningful advantage to investors over the medium and long term.
| 
